PK IDIQ- Post-market Bioequivalence of Generic Drug Products

The contract titled "PK IDIQ- Post-market Bioequivalence of Generic Drug Products" is an indefinite delivery, indefinite quantity (IDIQ) forecast opportunity issued by the Food and Drug Administration (FDA). It focuses on evaluating the bioequivalence of generic drug products after they have entered the market, ensuring that these generics maintain the same therapeutic efficacy and safety standards as their brand-name counterparts. The contract aligns with NAICS code 541714, which pertains to research and development in biotechnology. While specific location details and agency office addresses are not provided, the contract involves performance within the regulatory framework of the FDA. Key contacts include a program point of contact reachable through the FDA's CDER acquisitions email and a contracting officer whose identity and contact details are yet to be determined. This contract underscores the FDA's ongoing commitment to monitoring the quality and effectiveness of generic drugs for public health assurance.